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Abstract
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients requiring initial
therapy are often older and frailer and unsuitable candidates for standard chemoimmunotherapy
regimens. Shorter duration combination monoclonal antibody (mAb) therapy using alemtuzumab
and rituximab has been shown to be effective and tolerable treatment for CLL. Standard dose antiCD20 mAb therapy causes loss of CD20 expression by surviving CLL cells, which can be
minimized by decreasing the mAb dose. We report a randomized phase II clinical trial enrolling

Corresponding Author: Clive S. Zent MD, Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmswood Avenue
Box 704, Rochester NY 14642, Telephone: 585 276 6891, Fax: 585 276 3050, clive_zent@urmc.rochester.edu.

Zent et al.

Page 2

Author Manuscript

older (≥65 years) patients (median age 76 years, n=31) with treatment naïve progressive CLL.
Patients received 8–12 weeks of standard subcutaneous alemtuzumab with either intravenous
standard (375 mg/m2 weekly)(n=16) or low dose (20 mg/m2 3x week)(n=15) rituximab. This
study was closed before full accrual because the manufacturer withdrew alemtuzumab for
treatment of CLL. The overall response rate was 90% with an 45% complete response rate,
median progression free survival of 17.9 months and no significant differences in outcome
between the low and standard dose rituximab arms. The major toxicities were cytopenia and
infection with one treatment fatality caused by progressive multifocal leukoencephalopathy but no
other opportunistic infections. Combination mAb therapy was effective and tolerable treatment for
older and frailer patients with progressive CLL, achieving a high rate of complete remissions.
These data support the role of mAb in therapy for less fit CLL patients and the further study of
low dose higher frequency anti-CD20 mAb therapy as a potentially more effective use of antiCD20 mAb in the treatment of CLL.
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Introduction
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The median age at diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL) is 71 years [1]. Approximately 90% of CLL patients do not require treatment at
diagnosis and by the time that therapy is indicated, many are elderly and frail and thus not
suitable candidates for standard chemoimmunotherapy regimens [2, 3]. There is thus a need
to develop effective and less toxic therapy options for this patient population.
Alemtuzumab and rituximab are unconjugated monoclonal antibodies (mAb) that target
discrete CLL membrane antigens and utilize the innate immune system to kill CLL cells [4,
5]. Combination therapy with alemtuzumab and rituximab achieved high response rates in
phase II studies [6–10]. Although these response rates are higher than those previously
reported for monotherapy with either mAb [6–11], there are no reported randomized studies
showing conclusively that the addition of rituximab to alemtuzumab therapy in CLL patients
improves outcome. However, the alemtuzumab and rituximab regimen was well tolerated
and thus considered an option for non-chemotherapy initial treatment of elderly patients
with progressive CLL.

Author Manuscript

There are limited data on the optimal dosing regimen for rituximab in CLL. Previously
published studies have shown that higher frequency low dose therapy can decrease the loss
of CD20 expression by circulating CLL cells that occurs with standard dose rituximab
therapy [12–14]. In this paper we report the results of one of the first clinical trials in CLL
designed specifically for older CLL patients using a non-chemotherapy combination therapy
that tested the utility of use of higher frequency low dose rituximab. Our study shows that
short duration alemtuzumab and rituximab at both standard and low dose higher frequency
administration can achieve a high remission and complete rate in this patient population.
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These responses were achieved with acceptable rates of toxicity but were unfortunately not
of sufficient duration to consider this a major therapeutic advance.

Methods
Patient Selection

Author Manuscript

This randomized two-arm phase II study was designed to evaluate the efficacy and toxicity
of alemtuzumab and either standard or higher frequency low dose rituximab in older patients
with treatment naïve progressive CLL. The study was conducted by the ECOG-ACRIN
Cancer Research Group with participating Institutional Review Boards approval according
to the principles of the Declaration of Helsinki and was registered with Clinicaltrials.gov
(NCT01013961). The primary objective was to compare the rates of complete response (CR)
and overall response rates (ORR) of patients treated with standard and modified dose of
rituximab. The secondary objectives were to assess the toxicity of these regimens and to
determine the rates of progression-free survival (PFS) and overall survival (OS).

Author Manuscript

All eligible and consenting patients were enrolled in the study. Eligibility required that
patients had progressive treatment naïve CLL or its small lymphocytic lymphoma variant
based on standard criteria [15, 16] without massive splenomegaly (> 6 cm below the costal
margin in the left mid clavicular line) or lymphadenopathy > 5 cm on clinical examination.
The initial eligibility criteria required that patients be ≥ 70 years old but this was modified to
≥65 years on April 25, 2012. Patients were required to have an ECOG performance status of
0–3, and adequate organ function defined as a serum creatinine < 2 x upper normal limit for
treating institution (UNL), total bilirubin < 1.5 x UNL or direct bilirubin < 1.5 X UNL and
AST < 3.0 x UNL unless due to CLL involvement of the liver. Exclusion criteria were New
York Heart Association Class III-IV heart disease, recent myocardial infarction,
uncontrolled infection, HIV infection, active hepatitis B infection, positive hepatitis C
serology, active autoimmune cytopenia, other active primary malignancy requiring treatment
or that limits survival to ≤ 2 years, recent major surgery, or continuous systemic
corticosteroid therapy.
Therapy

Author Manuscript

Patients were randomized 1:1 to alemtuzumab and standard dose rituximab (arm A) or
alemtuzumab and higher frequency low dose rituximab (arm B) using risk stratification
based FISH analysis done at a central reference laboratory. Patients with 17p13 deletion or
11q22 deletion were considered high risk, those with 13q14 deletion as the sole detected
abnormality were considered low risk and those with no detected abnormalities, trisomy 12,
or other any other abnormality were considered intermediate risk. The first cycle of therapy
was 33 days to facilitate alemtuzumab dose escalation and the second and third cycles were
28 days. Alemtuzumab therapy was administered subcutaneously with a dose escalation of 3
mg day 1 (Wednesday), 10 mg day 2, and 30 mg day 3 of cycle 1. In patients who tolerated
dose escalation, the alemtuzumab therapy continued at 30 mg three times a week (MondayWednesday-Friday) starting on day 6 of cycle 1. Patients on arm A received rituximab 375
mg/m2/week IV starting on day 8 of cycle 1 and continued weekly. Patients on arm B
received rituximab 20 mg/m2 IV Monday, Wednesday and Friday starting on day 6 of cycle
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1. Planned therapy was a minimum of two cycles. Patients with a clinical complete response
(CCR) after two cycles of therapy underwent a more comprehensive response evaluation
(detailed below) and therapy was stopped if they had achieved a CR. Patients with
responding disease who had not achieved a CR received one additional cycle of therapy.

Author Manuscript

All patients received Pneumocystis jiroveci and herpes virus prophylaxis during therapy and
then for 6 months after the last dose of alemtuzumab. Monitoring for cytomegalovirus
(CMV) reactivation by serum CMV DNA copy number polymerase chain reaction (PCR)
assays was initiated prior to therapy and then done every week during treatment and then
monthly for two months after completion of therapy. In asymptomatic patients with
detectible CMV viremia the treatment regimen was continued and they were treated with
oral valganciclovir for at least 2 weeks and until the CMV antigenemia was shown to have
resolved by repeat serum CMV PCR assays done one week apart. Patients with CMV
viremia and clinical manifestations of infection were treated for infection as appropriate and
CLL therapy was held until full recovery.
Response Evaluation

Author Manuscript

Toxicity was evaluated using the NCI Common Toxicity Criteria version 4.0. Patients were
evaluated for response with National Cancer Institute-Working Group (NCI-WG 1996)
criteria and computerized tomography (CT) and bone marrow evaluations compatible with
the International Workshop on CLL updated NCI-WG criteria (IWCLL 2008) [15, 17].
After two cycles of therapy all patients with a CCR underwent a CT scan of chest-abdomenpelvis. Patients with no evidence of residual adenopathy or hepatosplenomegaly proceeded
to a bone marrow study including immunohistochemical staining (IHC) for residual disease.
All patients with a CR without any evidence of residual CLL on CT and IHC did not receive
any further therapy and did not undergo any additional response evaluation. All patients
completing three cycles of therapy who met criteria for at least a partial response (PR) had a
CT scan of chest-abdomen-pelvis and a bone marrow study two months after completing
therapy to assess response to therapy.
Statistical Methods

Author Manuscript

Patients were stratified by FISH analysis results into high, intermediate and low risk groups
and then randomized 1:1 to arms A and B using permuted blocks with dynamic balancing on
main institutions [18]. The primary aim of this study was to compare the rates of CR and
ORR of patients treated with either standard or higher frequency low dose rituximab. We
assumed a CR rate of 35% for patients receiving standard dose rituximab and targeted a 65%
CR rate for patients receiving the higher frequency low dose rituximab. Based on these
assumptions, accrual of 90 patients (80 eligible) randomized equally to the two arms had a
90% power to detect a 30% improvement in CR rate at a one-sided 0.1 significance level.
The study was to be stopped if the CR rate of the modified dose group was lower than the
standard dose group in the first 40 eligible patients. The study was also to be stopped if we
observed 5 or more patients with a grade 4 or higher non-hematological adverse event
related to treatment in the first 15 patients. OS was defined as the time from randomization
to death from any cause. Patients still alive were censored at the date of last contact. PFS
was defined as the time from entry onto study until CLL progression or death from any
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cause without documented progression. Patients without progression were censored at the
date of last disease assessment, unless death occurred within three months following the date
they were last known to be progression free. Kaplan-Meier estimates [19] were used for
event-time distributions. The response frequencies were computed using the maximum
likelihood estimate (the observed proportion of responses). Confidence intervals for
response frequencies were computed using the exact binomial distribution. Fisher’s exact
test was used to compare the response rates.

Results

Author Manuscript

E1908 opened to accrual on October 8, 2010 and closed on October 31, 2013. The study
only enrolled 31 of the planned 90 patients and was closed early because of poor accrual.
The decrease in the accrual rate was primarily caused by the withdrawal of alemtuzumab for
the treatment of CLL by the manufacturers for non-medical reasons and the rapid
development of successor clinical trials using novel targeted kinase inhibitors. Accrual to the
study was open to members of ECOG-ACRIN, NCCTG, CALGB and SWOG. Patients were
accrued by eight members (Mayo Clinic Rochester n=11, University of Wisconsin Hospital
and Clinic n=8, Illinois CancerCare ORA COPP n=5, Dayton CCOP n=3, and one each by
Penn State Medical Center, Gunderson Lutheran Health System CCOP, University of North
Carolina at Chapel Hill, and University of Tennessee Health Science Center). This analysis
reports on clinical data as of July 20, 2015. All enrolled patients were eligible, received
treatment and were included in the analysis. Patient characteristics are summarized in Table
I. The median age of 76 year (range 67–92) at age of study entry reflects the eligibility
criteria with only three patients aged < 70 years enrolled after the age limit was lowered.

Author Manuscript

Twenty five patients (13 arm A and 12 arm B) completed treatment according to protocol
with four receiving only two cycles of therapy because of achievement of CR with negative
CT and negative bone marrow IHC minimal residual disease examination. Six patients (3 in
each arm) did not complete therapy per protocol. Four stopped therapy because of toxicity,
one patient in arm A decided to withdraw from the study and one patient in arm B stopped
therapy at their physician’s discretion because of deteriorating clinical condition without
objective evidence of disease progression. Twenty two patients (eleven in each arm) had
three cycles of therapy, seven (4 arms A and 3 arm B) had two cycles of therapy and two
patients (one in each arm) had one cycle of therapy.
Treatment toxicity

Author Manuscript

Serious (> grade 2) adverse events at least possibly attributable to treatment are summarized
in Table II. One patient (arm A) developed fatal progressive multifocal leukoencephalopathy
(PML) and died 165 days after treatment initiation. Two additional patients had serious local
infections and neutropenic fever occurred in the 3 of the 19 patients with grade 3–4
neutropenia. Of note, neutropenia occurred in more patients on standard dose rituximab (12
of 16, 75%) compared to patients on lower dose rituximab (7 of 15, 47%) but this difference
was not statistically significant (p=0.15). Fifteen patients had CMV viremia with a median
peak viral load of 2000 copies/ml (range of 398 – 55000) and were treated with
valganciclovir with no treatment protocol interruptions and no hospitalizations.
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Response—Twenty-eight patients (90%) responded to therapy with 14 (45%) CR, 3
(10%) CCR, and 11 (35%) PR. The ORR for higher frequency low dose rituximab treated
patients (arm B) of 93.3% (14/15, 95% CI 68.1% – 99.8%) was not significantly different
from the standard dose rituximab therapy (arm A) of 87.5% (14/16, 95% CI 61.7% – 98.5%)
(p=1.0). The CR rate of 40% (6/15, 95% CI 16.3% – 67.7%) for arm B was not significantly
different from the 50% (8/16, 95% CI 24.7% – 75.3%) for arm A (p =0.7).

Author Manuscript

Response duration—The median PFS for all patients was 17.9 months (95% confidence
interval (CI) 12.4 – not achieved (NA)). The median PFS for arm B was longer than arm A
but with overlapping confidence intervals (23.3 months, 95% CI 14.8 – NA vs. 12.8 months
95% CI 11.7 – NA) (Figure 1). Twenty-three patients were still alive with a median follow
up time of 24.6 months (range 14.7 – 41.9 months). The median OS for the two arms have
not been reached (Figure 2).

Discussion
We report a US Intergroup clinical trial testing a novel therapy for older patients with
treatment naïve CLL. The regimen was designed to provide CLL patients with a tolerable
response modulated alternative to chemo-immunotherapy. Treatment achieved high ORR
and CR rates with tolerable toxicity but relatively short PFS. The treatment regimen became
less accessible during the course of the trial because of withdrawal of alemtuzumab for CLL
therapy and less likely to be used because of the remarkable and rapid development of
targeted kinase inhibitor therapy for CLL. However, the study data remain informative for
improving anti-CD20 mAb therapy in CLL.

Author Manuscript
Author Manuscript

The major toxicities of therapy with alemtuzumab and rituximab result from normal
lymphocyte depletion. One patient in this study died from PML, which could be attributed to
therapy-induced immunosuppression. PML has a reported incidence of 11 per 100,000 CLL
patients per year. Although the most frequently reported association of PML in CLL patients
has been with treatment regimens containing fludarabine and rituximab, PML has also been
reported as a complication in treatment naïve CLL patients and those treated with
alemtuzumab [20–22]. Previous studies of alemtuzumab containing regimens for the
treatment of CLL reported high rates of Pneumocystis jiroveci, varicella zoster or herpes
simplex related complications [23–25]. Antimicrobial prophylaxis was standard in this study
and no patients had these complications. In previously reported studies of alemtuzumab as
initial treatment of CLL the symptomatic CMV infection rate was 10 – 16% [23, 24]. Our
use of a prospective weekly CMV monitoring approach showed a higher than expected rate
of CMV reactivation in 15 patients (48%). This resulted from detecting subclinical
reactivations and treatment of all 15 (48%) viremic patients avoided clinically evident CMV
infection. We conclude that while opportunistic complications of CLL and its treatment such
as PML are still unavoidable, a standardized pre-emptive approach to the common infectious
complications can effectively manage the risk of infections with available prophylactic or
preventative therapies. These data could be useful for managing patients with hematological
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diseases such as T-cell prolymphocytic leukemia in which alemtuzumab remains an
important therapeutic option.
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Cytopenias were the most common serious adverse events in this study. The clinical
significance of this finding is difficult to interpret because of use of the standard NCI
Common Toxicity Criteria version 4, which does not account for pre-treatment cytopenias in
CLL. Unfortunately the more appropriate grading scale for hematological toxicities in CLL
studies currently used in many CLL studies [17] was not yet available during the planning of
this study. The most common cytopenia was neutropenia (61%), which was complicated by
neutropenic fever in three patients. Therapy with anti-CD20 mAb including rituximab and
therapy with alemtuzumab can decrease neutrophil counts by mechanisms that are not fully
understood [26, 27]. Of particular interest was the non-significant difference in the severe
neutropenia rates in patients treated with low dose rituximab (7/15, 47%) compared to those
on standard dose rituximab (12/16, 75%), which suggests that higher dose rituximab therapy
could increase the risk of neutropenia.

Author Manuscript

There are no data from randomized controlled trials to determine if addition of rituximab to
alemtuzumab therapy for CLL improves outcome. Previous clinical trials using
alemtuzumab for initial treatment of progressive CLL resulted in high ORR as assessed by
NCI-WG 1996 criteria. In a phase II trial enrolling 41 treatment naïve patients (median age
66 years) with progressive CLL for 18 weeks of therapy with subcutaneous alemtuzumab
(planned therapy 18 weeks) the ORR was 87% with CR of 19% and the median time to
treatment failure exceeded 18 months [23]. Similar results were achieved in the subset of 20
patients aged ≥65 years (ORR 90%, CR 20%) [23]. In a randomized phase III trial
comparing IV alemtuzumab to chlorambucil for initial therapy of progressive CLL, the 149
patients in the alemtuzumab cohort (median age 59 years) had an ORR of 83% with 24%
CR and median PFS of 11.7 months [24]. The subset of 53 patients on the alemtuzumab arm
aged ≥65 years had a similar reported outcome (ORR 76% and median PFS 12.5 months). In
our study the CR rate using more rigorous IWCLL 2008 compatible response criteria
including CT scans was 45%. This suggests that addition of rituximab to alemtuzumab could
improve the depth of response to treatment and possible also the PFS.
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There has been a considerable progress in improving CLL therapies for less fit patients.
Addition of anti-CD20 mAbs to oral chlorambucil has been shown to improve the quality
and duration of responses. A clinical trial enrolling a total of 781 patients (median age 73
years) requiring initial treatment for progressive CLL randomized patients to chlorambucil
alone or in combination with either rituximab or obinutuzumab with responses assessed with
IWCLL 2008 criteria [28]. Compared to an ORR rate of 31% (no CR, median PFS 11
months) with chlorambucil monotherapy, addition of rituximab significantly increased the
ORR rate to 66% (7% CR, median PFS 16 months) and addition of obinotuzumab
significantly increased the ORR to 77% (22% CR, median PFS 27 months). Another large
clinical trial enrolled 447 patients (median age 69 years) requiring initial therapy for
progressive CLL who were randomized to chlorambucil monotherapy or chlorambucil and
ofatumumab [29]. The responses were significantly higher in the patients treated with
chlorambucil and ofatumumab (ORR 82% vs 69%, CR 14% vs. 1%, median PFS 22 vs. 13
months). A recently reported phase II study of combination initial therapy for 70 elderly
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patients (median age 72 years) with CLL using bendamustine and rituximab achieved a
ORR of 89% with 31% CR and median PFS of 79% at 2 years [30]. The mAb combination
therapy used in our trial achieved an ORR and CR comparable to these
chemoimmunotherapy regimens but with a shorter PFS. The reason for this discrepancy is
currently unknown and further investigation could be informative about the differences in
the cytotoxic effects of mAb compared to DNA damaging agents.
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To the best of our knowledge this is the first study to randomize patients to either a higher
frequency low dose or standard dose anti-CD20 mAb therapy. Use of the lower dose
regimen did not appear to affect ORR or CR rates with no significant difference in PFS but
these data have to be considered preliminary because of the small sample size. An additional
potential advantage of the low dose rituximab regimen could be a decreased risk of
iatrogenic neutropenia. The need to administer rituximab IV three times a week did increase
the logistical burden on patients randomized to arm B of the study, but the development of
subcutaneous formulations for rituximab and ofatumumab could allow patients to be trained
to self-administer low doses of these mAb at home as was done for alemtuzumab for many
patients on this study. These data add to the preclinical data [31–34] and clinical study data
[12–14] that suggest that subcutaneous low dose higher frequency anti-CD20 mAb therapy
could be a better therapy for CLL than currently used regimens. The addition of low dose
higher frequency anti-CD20 mAb therapy to B-cell receptor pathway inhibitors could
potentially improve the efficacy and safety of therapy for CLL.
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The strengths of this study include treatment at eight sites including a mix of academic and
community based centers, inclusion of an older population with predominantly advanced
stage disease and a high proportion of genetically high risk disease, and the use of imaging
and bone marrow immunohistochemistry to determine responses to treatment. The study
also shows that a shorter duration combination antibody therapy can be effectively
administered with tolerable toxicity and achieve a high response rate. The major limitation
of this study is the limited accrual due to immutable circumstances. The paradigm shift in
management of CLL that occurred during the conduct of this clinical trial markedly
decreased the clinical value of our data on use of alemtuzumab for treatment of older
patients with CLL. Despite these limitations, this study does provide preliminary data that
could be useful in improving use of anti-CD20 mAb therapy, which continues to be very
valuable in the treatment of CLL and other B cell malignancies.
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In conclusion, we present data showing that a mAb combination therapy was effective and
tolerable therapy for the initial treatment of progressive CLL in older patients. Although this
regimen has been superseded by progress in targeted drug development, the data on the use
of anti-CD20 mAb is informative for designing future clinical trials and correlative studies
to optimize use of this class of drugs that continues to have an important role in the
management of this incurable disease.
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Figure 1. Progression free survival

The median progression free survival for patients treated with standard dose rituximab (arm
A) was 12.8 months with a 95% confidence interval (CI) of 11.7 – not achieved (NA) and
for patients treated with higher frequency low dose rituximab (arm B) was 23.3 months with
95% CI of 14.8 – NA.

Author Manuscript
Am J Hematol. Author manuscript; available in PMC 2017 March 01.

Zent et al.

Page 12

Author Manuscript
Author Manuscript
Figure 2. Overall Survival
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Median overall survival has not been reached for either treatment arm with 23 surviving
patients having a median follow up time of 24.6 months (range 14.7 – 41.9 months).
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Table I

Author Manuscript

Patient Characteristics
A
n=16
Age (years)

Gender*

Performance status (ECOG)

Clinical Stage (Rai)

Author Manuscript

Risk Stratification (FISH)

B
n=15

All
n=31

Median

77

76

76

Range

67–92

68–86

67–92

Male

10 (62.5)

8 (53.3)

18 (58.1)

Female

6 (37.5)

7 (46.7)

13 (41.9)

0

10 (62)

4 (27)

14 (45)

1

5 (31)

10 (67)

15 (48)

2

1 (6)

1 (7)

2 (6)

0

0 (0)

1 (7)

1 (3)

I

3 (19)

1 (7)

4 (13)

II

1 (6)

1 (7)

2 (6)

III

7 (44)

9 (60)

16 (52)

IV

5 (31)

3 (20)

8 (26)

High#

5 (31)

4(27)

9 (29)

Intermediate

6 (38)

6 (40)

12 (39)

Low

5 (31)

5 (33)

10 (32)

*

number of patients and (%)

#

Five patients with 17p13 deletion (3 on arm A and 2 on arm B) and 4 patients

with 11q22 deletion (2 on each arm)
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Table II

Author Manuscript

Severe Adverse Events
Adverse Event*

A
n=16

B
n=15

Total

Anemia

1

1

2

Febrile neutropenia

2

1

3

Neutropenia

12

7

19

Thrombocytopenia

3

1

4

Fatigue

2

1

3

2

2

Rash
Mucositis

1

Serum sickness
Infection - lung

1
1

1

1

1

Author Manuscript

Infection - tooth

1

1

Infection - CNS

1#

1

Lipase increased

1

1

Weight loss

1

1

Hyponatremia

1

1

2

*

greater than grade 2 toxicity at least possibly attributable to treatment

#

patient died of progressive multifocal leukoencephalopathy

Author Manuscript
Author Manuscript
Am J Hematol. Author manuscript; available in PMC 2017 March 01.

